The upregulation of CD44, FN1, MMP1, MMP9, SNAI1, and VEGFA, especially within the wild-type IDH1R132 GBM group, emphasises the suitability of 3D cultures as preclinical substitutes for treatment-resistant models by simulating the EMT process and increased migratory capacity. The gene discussed is MMP1; the disease is glioblastoma.